RespireRx Pharmaceuticals Inc (RSPI)

[apu_85]

They hired a leading advisory firm and I think a big part is to strategize about what a partnership for dronabinol looks like. Given the massive commercial market, strong phase II results, and potential for expedited approval, I think they have offers and funding possibilities. Getting the right deal will be critical which is why I think they are taking their time. That leaves funding for ampakines in question. Pretty quiet on that front despite quite ambitious milestones planned for next couple years.